Provention Bio yesterday closed its initial public offering, raising approximately $63.9 million.
Funds from the round will help support the Oldwick, N.J.-based company’s clinical-stage biopharmaceuticals that aim to prevent or intercept immune-mediated diseases.
Provention Bio said that it expects shares of its common stock will begin trading on Nasdaq under the ticker symbol “PRVB” next Tuesday. The company offered shares at $4 per during the initial public offering.
MDB Capital Group acted as the sole book-runner for the offering, with Dougherty & Co. acting as a qualified independent underwriter, according to a press release.
Last July, Provention Bio announced an interest in researching and producing vaccine technology intended to prevent the onset of Type 1 diabetes.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.